Posted Jun. 18, 2013 at 7:56 p.m.

Premium Lock Dara licenses diabetes compound to new RTP firm with CNS focus

Published: 2013-06-18 19:56:18
Updated: 2013-06-18 19:56:18

DARA DARA

Dara BioSciences spent years developing DB959 for diabetes. Now it's been licensed to T3D Therapeutics, which plans to study it in Alzheimer's disease. Read why T3D is a good fit for DB959's new focus....

Read More
Read More

WRAL TechWire any time: Twitter, Facebook

Copyright 2014 WRAL TechWire. All rights reserved.
Editor's Blog

Editor's Blog

The latest blog posts from our WRAL TechWire and WRAL editors. Read more articles…

Please Log In to add a comment.

Best of TechWire Insider

Techwire Inside Partners

OUR INSIDERS

Dr. Mike Walden
Tech economy
Vivek Wadhwa
Commentary
Frank Vinluan
Life science
Scroll